CYC Stock Overview
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cyclopharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.51 |
| 52 Week High | AU$1.97 |
| 52 Week Low | AU$1.33 |
| Beta | 0.71 |
| 1 Month Change | 10.22% |
| 3 Month Change | 4.86% |
| 1 Year Change | -20.94% |
| 3 Year Change | -7.36% |
| 5 Year Change | 31.30% |
| Change since IPO | -19.47% |
Recent News & Updates
Recent updates
What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash
Oct 28
Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?
Apr 18Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth
Mar 31Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth
Oct 17Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth
Jun 09Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher
Mar 06Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation
Mar 02We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth
Oct 22Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates
Jun 29Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being
Apr 27Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic
Mar 01Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment
Feb 07Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?
Jan 02We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate
Dec 06Shareholder Returns
| CYC | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -8.2% | -1.1% | -2.7% |
| 1Y | -20.9% | 0.4% | 6.5% |
Return vs Industry: CYC underperformed the Australian Medical Equipment industry which returned 0.4% over the past year.
Return vs Market: CYC underperformed the Australian Market which returned 6.5% over the past year.
Price Volatility
| CYC volatility | |
|---|---|
| CYC Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: CYC has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CYC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 87 | James McBrayer | www.cyclopharm.com |
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism.
Cyclopharm Limited Fundamentals Summary
| CYC fundamental statistics | |
|---|---|
| Market cap | AU$167.82m |
| Earnings (TTM) | -AU$9.32m |
| Revenue (TTM) | AU$24.06m |
7.0x
P/S Ratio-18.0x
P/E RatioIs CYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYC income statement (TTM) | |
|---|---|
| Revenue | AU$24.06m |
| Cost of Revenue | AU$10.23m |
| Gross Profit | AU$13.82m |
| Other Expenses | AU$23.14m |
| Earnings | -AU$9.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.084 |
| Gross Margin | 57.47% |
| Net Profit Margin | -38.72% |
| Debt/Equity Ratio | 0% |
How did CYC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:17 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cyclopharm Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | Barclay Pearce Capital Pty Limited |
| John Hester | Bell Potter |
| Sarah Mann | MA Moelis Australia Securities Pty Ltd |